These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


PUBMED FOR HANDHELDS

Journal Abstract Search


217 related items for PubMed ID: 15352656

  • 21. [Multicenter study of darbepoetin alfa in the treatment of anemia secondary to chronic renal insufficiency on dialysis].
    Martínez Castelao A, Reyes A, Valdés F, Otero A, López de Novales E, Pallardó L, Tabernero JM, Hernández Jaras J, Lladós F.
    Nefrologia; 2003; 23(2):114-24. PubMed ID: 12778875
    [Abstract] [Full Text] [Related]

  • 22. Epoetin alfa 60,000 U once weekly followed by 120,000 U every 3 weeks increases and maintains hemoglobin levels in anemic cancer patients undergoing chemotherapy.
    Patton J, Kuzur M, Liggett W, Miranda F, Varsos H, Porter L.
    Oncologist; 2004; 9(1):90-6. PubMed ID: 14755018
    [Abstract] [Full Text] [Related]

  • 23. Early Intervention with epoetin alfa during platinum-based chemotherapy: an analysis of quality-of-life results of a multicenter, randomized, controlled trial compared with population normative data.
    Savonije JH, van Groeningen CJ, Wormhoudt LW, Giaccone G.
    Oncologist; 2006 Feb; 11(2):197-205. PubMed ID: 16476840
    [Abstract] [Full Text] [Related]

  • 24. Use of latent growth curve models for assessing the effects of darbepoetin alfa on hemoglobin and fatigue.
    Stull DE, Vernon MK, Legg JC, Viswanathan HN, Fairclough D, Revicki DA.
    Contemp Clin Trials; 2010 Mar; 31(2):172-9. PubMed ID: 20060499
    [Abstract] [Full Text] [Related]

  • 25. Randomized comparison of every-2-week darbepoetin alfa and weekly epoetin alfa for the treatment of chemotherapy-induced anemia: the 20030125 Study Group Trial.
    20030125 Study Group TrialUniversity of California Los Angeles School of Medicine, Los Angeles, CA 90095, USA. jglaspy@mednet.ucla.edu, Glaspy J, Vadhan-Raj S, Patel R, Bosserman L, Hu E, Lloyd RE, Boccia RV, Tomita D, Rossi G.
    J Clin Oncol; 2006 May 20; 24(15):2290-7. PubMed ID: 16710026
    [Abstract] [Full Text] [Related]

  • 26. Randomized, controlled trial of darbepoetin alfa for the treatment of anemia in hemodialysis patients.
    Nissenson AR, Swan SK, Lindberg JS, Soroka SD, Beatey R, Wang C, Picarello N, McDermott-Vitak A, Maroni BJ.
    Am J Kidney Dis; 2002 Jul 20; 40(1):110-8. PubMed ID: 12087568
    [Abstract] [Full Text] [Related]

  • 27. Randomized double-blind trial of darbepoetin alfa in patients with symptomatic heart failure and anemia.
    Ghali JK, Anand IS, Abraham WT, Fonarow GC, Greenberg B, Krum H, Massie BM, Wasserman SM, Trotman ML, Sun Y, Knusel B, Armstrong P, Study of Anemia in Heart Failure Trial (STAMINA-HeFT) Group.
    Circulation; 2008 Jan 29; 117(4):526-35. PubMed ID: 18195176
    [Abstract] [Full Text] [Related]

  • 28. Clinical evaluation of once-weekly dosing of epoetin alfa in chemotherapy patients: improvements in hemoglobin and quality of life are similar to three-times-weekly dosing.
    Gabrilove JL, Cleeland CS, Livingston RB, Sarokhan B, Winer E, Einhorn LH.
    J Clin Oncol; 2001 Jun 01; 19(11):2875-82. PubMed ID: 11387360
    [Abstract] [Full Text] [Related]

  • 29. A randomized, active-control, pilot trial of front-loaded dosing regimens of darbepoetin-alfa for the treatment of patients with anemia during chemotherapy for malignant disease.
    Glaspy JA, Jadeja JS, Justice G, Fleishman A, Rossi G, Colowick AB.
    Cancer; 2003 Mar 01; 97(5):1312-20. PubMed ID: 12599240
    [Abstract] [Full Text] [Related]

  • 30. Evaluation of the US Oncology Network's recommended guidelines for therapeutic substitution with darbepoetin alfa 200 microg every 2 weeks in both naïve patients and patients switched from epoetin alfa.
    Thames WA, Smith SL, Scheifele AC, Yao B, Giffin SA, Alley JL.
    Pharmacotherapy; 2004 Mar 01; 24(3):313-23. PubMed ID: 15040644
    [Abstract] [Full Text] [Related]

  • 31. Darbepoetin alfa administration to achieve and maintain target hemoglobin levels for 1 year in patients with chronic kidney disease.
    Hertel JE, Locay HR, Scarlata DS, Prathikanti R, Audhya PK.
    Mayo Clin Proc; 2006 Sep 01; 81(9):1188-94. PubMed ID: 16970215
    [Abstract] [Full Text] [Related]

  • 32. [Darbepoetin-alfa treatment of anemia secondary to chronic renal failure in dialysis patients: Results of a French multicenter study].
    Kessler M, Hannedouche T, Fitte H, Cayotte JL, Urena P, Réglier JC, Groupe de l'étude NESP 20000117.
    Nephrol Ther; 2006 Sep 01; 2(4):191-9. PubMed ID: 16966064
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. Treatment of chemotherapy-induced anemia in breast cancer: results of a randomized controlled trial of darbepoetin alfa 200 microg every 2 weeks versus epoetin alfa 40,000 U weekly.
    Senecal FM, Yee L, Gabrail N, Charu V, Tomita D, Rossi G, Schwartzberg L.
    Clin Breast Cancer; 2005 Dec 01; 6(5):446-54. PubMed ID: 16381629
    [Abstract] [Full Text] [Related]

  • 35. Darbepoetin alfa effectively treats anemia in patients with chronic kidney disease with de novo every-other-week administration.
    Toto RD, Pichette V, Navarro J, Brenner R, Carroll W, Liu W, Roger S.
    Am J Nephrol; 2004 Dec 01; 24(4):453-60. PubMed ID: 15331889
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. Initiation of epoetin-alpha therapy at a starting dose of 120,000 units once every 3 weeks in patients with cancer receiving chemotherapy: an open-label, multicenter study with randomized and nonrandomized treatment arms.
    Glaspy JA, Charu V, Luo D, Moyo V, Kamin M, Wilhelm FE.
    Cancer; 2009 Mar 01; 115(5):1121-31. PubMed ID: 19170225
    [Abstract] [Full Text] [Related]

  • 40. Darbepoetin alfa administered every 2 weeks alleviates anemia in cancer patients receiving chemotherapy.
    Glaspy JA, Tchekmedyian NS.
    Oncology (Williston Park); 2002 Oct 01; 16(10 Suppl 11):23-9. PubMed ID: 12435170
    [Abstract] [Full Text] [Related]


    Page: [Previous] [Next] [New Search]
    of 11.